NCT03970122View on ClinicalTrials.gov

FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 29, 2019

Primary Completion Date

March 4, 2020

Study Completion Date

April 4, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

GFB-887

IMP

DRUG

Placebo

Matching

Trial Locations (1)

75247

Covance Clinical Research Unit Inc., Dallas

Sponsors
All Listed Sponsors
lead

Goldfinch Bio, Inc.

INDUSTRY